FY2026 Earnings Forecast for EYPT Issued By Chardan Capital

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Analysts at Chardan Capital issued their FY2026 earnings per share estimates for shares of EyePoint Pharmaceuticals in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin expects that the company will post earnings of ($2.82) per share for the year. Chardan Capital has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

Other analysts also recently issued research reports about the stock. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Stock Down 2.5 %

Shares of EYPT opened at $5.91 on Wednesday. EyePoint Pharmaceuticals has a 52-week low of $5.54 and a 52-week high of $23.65. The company has a market cap of $406.19 million, a PE ratio of -2.96 and a beta of 1.41. The business has a fifty day moving average of $6.82 and a 200 day moving average of $8.24.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. purchased a new position in shares of EyePoint Pharmaceuticals in the 4th quarter worth approximately $23,705,000. TCG Crossover Management LLC increased its position in shares of EyePoint Pharmaceuticals by 287.3% in the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company’s stock valued at $26,614,000 after acquiring an additional 2,650,000 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in EyePoint Pharmaceuticals by 51.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock worth $42,838,000 after acquiring an additional 1,958,580 shares during the last quarter. Federated Hermes Inc. lifted its position in EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock worth $27,620,000 after acquiring an additional 1,783,765 shares during the period. Finally, Suvretta Capital Management LLC grew its stake in EyePoint Pharmaceuticals by 31.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company’s stock valued at $50,534,000 after purchasing an additional 1,607,268 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.